


**AMENDMENTS TO THE CLAIMS**


Please amend the claims so that they read as follows:

1. (Original) A compound of the formula (I), their tautomeric and stereoisomeric form, and salts thereof:



wherein

A represents the formula



wherein

# represents the connection position to the molecule,

Q<sub>1a</sub> and Q<sub>4a</sub> independently represent direct bond or methylene,

Q<sub>2a</sub> represents CHR<sup>2a</sup>,

Q<sub>3a</sub> represents CHR<sup>3a</sup>,

wherein

R<sup>2a</sup> represents group hydrogen, hydroxy, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkanoyloxy, and


R<sup>3a</sup> represents hydrogen, hydroxy, C<sub>1-6</sub> alkoxy, or C<sub>1-6</sub> alkanoyloxy,

with the proviso that Q<sub>1a</sub> and Q<sub>4a</sub> can not be direct bond at the same time and

R<sup>2a</sup> and R<sup>3a</sup> can not be hydrogen at the same time,

and

E represents the formula



wherein

# represents the connection position to the molecule,

Q<sub>1b</sub>, Q<sub>2b</sub>, Q<sub>4b</sub> and Q<sub>5b</sub> independently represent C(R<sup>11b</sup>)(R<sup>12b</sup>),

wherein

R<sup>11b</sup> and R<sup>12b</sup> independently represent hydrogen, phenyl, benzyl, or C<sub>1-6</sub> alkyl optionally substituted by hydroxy, carboxy, phenyl, benzyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino;

Q<sub>3b</sub> represents C-R<sup>13b</sup>,

wherein

R<sup>13b</sup> represents hydrogen, phenyl, benzyl, or C<sub>1-6</sub> alkyl optionally substituted by hydroxy, carboxy, phenyl, benzyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino;

R<sup>1b</sup> represents C<sub>1-6</sub> alkyl substituted by aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>3-8</sub> cycloalkylamino, C<sub>1-6</sub> alkoxycarbonyl, phenyl, benzyl, heterocycle, sulfonamide, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkanoylamino, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, cyano, C<sub>1-6</sub> alkyl optionally substituted by cyano, C<sub>1-6</sub> alkoxycarbonyl or mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen, phenoxy optionally substituted by halogen or C<sub>1-6</sub> alkyl, or C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri-halogen, C<sub>3-8</sub> cycloalkyl, and heterocycle;

or

aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>3-8</sub> cycloalkylamino, C<sub>1-6</sub> alkoxy carbonyl, phenyl, benzyl, heterocycle, sulfonamide, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkanoylamino, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, cyano, C<sub>1-6</sub> alkyl optionally substituted by cyano, C<sub>1-6</sub> alkoxy carbonyl or mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri- halogen, phenoxy optionally substituted by halogen or C<sub>1-6</sub> alkyl, or C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri- halogen, C<sub>3-8</sub> cycloalkyl, and heterocycle;

na represents 1 or 2;

ma represents 0, 1, 2, or 3;

-X<sub>a</sub>- represents bond, -O- or -N(R<sup>1a</sup>)- (wherein R<sup>1a</sup> is hydrogen or C<sub>1-6</sub> alkyl);

and


R<sub>a</sub> represents aryl or heteroaryl

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl) amino, C<sub>3-8</sub> cycloalkylamino, C<sub>1-6</sub> alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>3-8</sub> cycloalkylamino, or C<sub>1-6</sub> alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl) amino, C<sub>3-8</sub> cycloalkylamino, or C<sub>1-6</sub> alkoxy carbonyl), sulfonamide, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkanoylamino, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, cyano, or a C<sub>1-6</sub> alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C<sub>1-6</sub> alkoxy carbonyl or mono-, di-, or tri-halogen), C<sub>1-6</sub> alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen, phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>3-8</sub>


cycloalkylamino, C<sub>1-6</sub> alkoxycarbonyl or C<sub>1-6</sub> alkyl), C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri- halogen), C<sub>3-8</sub> cycloalkyl, and heterocycle.

2. (Original) Compound of formula (I) according to claim 1, with the formula (Ib), their tautomeric and stereoisomeric form, and salts thereof:



wherein Q<sub>1b</sub>, Q<sub>2b</sub>, Q<sub>3b</sub>, Q<sub>4b</sub>, Q<sub>5b</sub> and R<sup>1b</sup> are the same as defined in claim 1.


3. (Original) Compound of formula (I) according to claim 1, with the formula (Ia), their tautomeric and stereoisomeric form, and salts thereof:



wherein Q<sub>1a</sub>, Q<sub>2a</sub>, Q<sub>3a</sub>, Q<sub>4a</sub>, na, ma, X<sub>a</sub> and R<sub>a</sub> are the same as defined in claim 1.


4. (Currently amended) A process for synthesizing the compounds of general formula (I), wherein formula (I) contains the compounds of formula (Ib) and (Ia), according to claim 1, characterized in that

[Method Ab]



a compound of the formula (Ib), wherein  $Q_{1b}$ ,  $Q_{2b}$ ,  $Q_{3b}$ ,  $Q_{4b}$ ,  $Q_{5b}$  and  $R^{1b}$  are the same as defined in claim 1, can be prepared by the reaction of the compound of the formula (IIb) with the compound of the formula (IIIb), wherein  $Q_{1b}$ ,  $Q_{2b}$ ,  $Q_{3b}$ ,  $Q_{4b}$ ,  $Q_{5b}$  and  $R^{1b}$  are the same as defined in claim 1 and  $L_{1b}$  represents a leaving group including, for instance, hydroxy, halogen atom such as chlorine, bromine, or iodine atom, or azole such as imidazole or triazole, or


[Method Aa]



a compound of the formula (IVa), wherein  $Q_{1a}$ ,  $Q_{2a}$ ,  $Q_{3a}$ , and  $Q_{4a}$ , are the same as defined in claim 1, can be prepared by the reaction of the compound of the formula (IIa), wherein  $Q_{1a}$ ,  $Q_{2a}$ ,  $Q_{3a}$ , and  $Q_{4a}$ , are the same as defined in claim 1, with the compound of the formula (IIIa), wherein  $L_{1a}$  represents a leaving group including, for instance, hydroxy, halogen atom such as chlorine, bromine, or iodine atom, or azole such as imidazole or triazole and  $L_{2a}$  represents a leaving group including, for instance, halogen atom such as chlorine, bromine, or iodine atom, or phenoxy, and then the compound of the formula (Va), wherein  $n_a$ ,  $m_a$ ,  $X_a$  and  $R_a$  are the same as defined in claim 1, is reacted with the compound (IVa) to obtain the compound of the formula (Ia), wherein  $Q_{1a}$ ,  $Q_{2a}$ ,  $Q_{3a}$ ,  $Q_{4a}$ ,  $n_a$ ,  $m_a$ ,  $X_a$  and  $R_a$  are the same as defined in claim 1,

or


[Method Ba]



a compound of the formula (Ia) can be prepared by the reaction of the compound of the formula (IIa) and the compound of the formula (VIa), wherein  $n_a$ ,  $m_a$ ,  $X_a$ , and  $R_a$  and  $L_{1a}$  are the same as defined in claim 1, and  $L_{1a}$  is a leaving group as defined above.

or


[Method Ca]



a compound of the formula (Ia) can be prepared by reacting the compound of the formula (IIa) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1'-carbonyldi(1,2,4-triazole)(CDT), and then adding the compound of the formula (Va) to the reaction mixture,

or

[Method Da]



a compound of the formula (Ia) can be prepared by reacting the compound of the formula (Va) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1'-carbonyldi(1,2,4-triazole)(CDT) and then adding the compound of the formula (IIa) to the reaction mixture.

5. (Currently Amended) A medicament comprising the derivative compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
6. (Currently amended) The medicament as claimed in claim [[4]] 5, further comprising one or more pharmaceutically acceptable excipients.
7. (Currently amended) The medicament as claimed in claim [[4]] 5, wherein said derivative compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.

Claims 8-16. (Canceled)

17. (Currently amended) ~~Process for controlling an~~ A method for treating a urological disorder or disease in ~~humans and animals by administration of a human or animal, comprising administering to the human or animal~~ a VR1-antagonistically effective amount of at least one compound according to claim 1.

18. (Currently amended) ~~Process for controlling~~ A method for treating a disorder or disease related to pain in ~~humans and animals by administration of a human or animal, comprising administering to the human or animal~~ a VR1-antagonistically effective amount of at least one compound according to claim 1.

19. (Currently amended) ~~Process for controlling~~ A method for treating an inflammatory disorder or disease in ~~humans and animals by administration of a human or animal, comprising administering to the human or animal~~ a VR1-antagonistically effective amount of at least one compound according to claim 1.

20. (New) The compound of claim 1, wherein the compound is selected from the group consisting of: 1-(2-Chlorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide; N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-(2-nitrophenyl)piperidine-4-carboxamide; N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-[2-nitro-4-(trifluoromethyl)phenyl]piperidine-4-carboxamide; 1-(2-Fluorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide; 1-(4-Fluorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide; 1-[4-Chloro-2-(trifluoromethyl)phenyl]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide; N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide; 1-[2-Chloro-4-(trifluoromethyl)phenyl]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide; 1-(4-Fluorophenyl)-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; 1-[2-Chloro-4-(trifluoromethyl)phenyl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; 1-[2-Chloro-4-(trifluoromethyl)phenyl]-N-[(7S)-7-hydroxy-5,6,7,8-tetrahydro-naphthalen-1-yl]piperidine-4-carboxamide; 1-[3-Chlorophenyl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-1-phenyl-5,6,7,8-tetrahydronaphthalen-1-



yl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[3-trifluoromethyl-phenyl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[3-trifluoromethoxy-phenyl]piperidine-4-carboxamide; 1-[2,4-Dichlorophenyl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; 1-[3,4-Bis(trifluoromethoxy)phenyl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[4-trifluoromethoxy-phenyl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[4-trifluoromethyl-pyrimidin-2-yl]piperidine-4-carboxamide; 1-[5-Chloropyrimidin-2-yl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; 1-[2-Chloro-4-nitrophenyl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; 1-[3-(Acetylamino)-5-(trifluoromethyl)pyridin-2-yl]-N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[5-(trifluoromethyl)-pyridin-2-yl]piperidine-4-carboxamide; N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-1-[4-trifluoromethyl-phenyl]piperidine-4-carboxamide; and salts thereof.

21. (New) The method of claim 17, wherein the urological disorder or disease is selected from detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms.

22. (New) The method of claim 18, wherein the disease or disorder related to pain is selected from neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.

23. (New) The method of claim 19, wherein the inflammatory disorder or disease is selected from asthma and COPD.

24. (New) The process of claim 4, wherein  $L_{1b}$  is hydroxy, halogen, or azole.

25. (New) The process of claim 24, wherein  $L_{1b}$  is chlorine, bromine, or iodine.

26. (New) The process of claim 24, wherein  $L_{1b}$  is an imidazole or triazole.

27. (New) The process of claim 4, wherein  $L_{1a}$  is hydroxy, halogen or azole.

28. (New) The process of claim 27, wherein  $L_{1a}$  is a chlorine, bromine or iodine.
29. (New) The process of claim 27, wherein  $L_{1a}$  is imidazole or triazole.
30. (New) The process of claim 4, wherein  $L_{2a}$  is a halogen atom or a phenoxy group.
31. (New) The process of claim 4, wherein  $L_{2a}$  is a chlorine, bromine or iodine.